10 results about "L929 cell" patented technology

The present invention discloses the preparation of an anti-inflammatory peptide derived from the hydrolysis of shell nacre protein and its application in skin repair. The peptide PDFDNGF provided by the invention can effectively promote the proliferation of RAW264.7 macrophage cells and inhibit the excessive production of nitric oxide and cytokines in RAW264.7 cells induced by lipopolysaccharide, while increasing the levels of anti-inflammatory cytokines, demonstrating significant anti-inflammatory activity. Furthermore, the active peptide has a significant proliferative effect on L929 cells, indicating its potential to promote skin wound healing. This invention provides a theoretical basis for the high-value utilization of shell nacre.

The invention discloses a gel microneedle loaded with silver nanoparticles and a preparation method and application thereof.The extract nano-silver (AB-AgNPs) is prepared through a green synthesis strategy, a drug-loaded microneedle system is constructed based on carboxymethyl chitosan-vanillic aldehyde-polyvinyl alcohol (CMCS-Va-PVA) composite gel, the AB-AgNPs prepared through the technology are uniform in particle size and stable in dispersion, and the drug-loaded microneedle has the advantages that the drug-loaded microneedle is good in drug-loaded performance and good in drug-loaded performance; the crystal has a typical face-centered cubic crystal structure and metal state Ag0 characteristics; the gel microneedle has good mechanical strength and forming effect, the AB-AgNPs and the gel matrix are stably combined through hydrogen bonds, the chemical properties are kept unchanged, and the system has broad-spectrum efficient bacteriostatic activity and biocompatibility; an in-vitro experiment proves that the green synthesized gel microneedle loaded with the silver nanoparticles has a remarkable capability of promoting the healing of L929 cell tissues; a rat wound experiment proves that the gel microneedle can regulate and control an inflammatory factor network and promote cell migration and tissue regeneration, healing of common and infected wounds is remarkably accelerated, and the wound residue ratio in 9 days is as low as 2.7% and 10.9% respectively.

The invention discloses a recombinant collagen, a coding gene and a preparation method and application thereof, and belongs to the technical field of gene engineering and protein engineering. On the basis of an amino acid sequence of human VII type collagen, the amino acid sequence is designed by means of bioinformatics and the like, a new recombinant collagen is constructed, further, a pichia pastoris strain for efficiently expressing the recombinant collagen is constructed by optimizing a gene sequence through codons, and the recombinant collagen is obtained. The recombinant collagen has good biocompatibility and biological activity, can remarkably promote proliferation, adhesion and migration of L929 cells, and has wide application prospects in multiple fields such as food, medicines, cosmetics or instrument products.

The invention discloses triple helix recombinant collagen as well as a preparation method and application thereof, and belongs to the technical field of gene engineering and protein engineering. According to the invention, on the basis of the amino acid sequence of natural collagen, the amino acid sequence is designed by means of bioinformatics and the like, a novel triple-helix recombinant collagen is constructed, and the triple-helix recombinant collagen has a good triple-helix structure, biocompatibility and biological activity, and can be used for preparing the collagen. The proliferation, the adhesion and the migration of the L929 cells can be obviously promoted, and the method has a wide application prospect in various fields such as food, medicines, cosmetics or instrument products.

This application belongs to the field of biomaterials, specifically relating to an antibacterial polymeric derivative of F127 with terminal modification of acetyl bromide, its preparation method, and its application. This application obtains F127AcBr by terminal modification of polymeric F127 with acetyl bromide via an acylation reaction. Its good antibacterial effect and biocompatibility were verified in vitro using plate antibacterial assays against Staphylococcus aureus and Escherichia coli, as well as live / dead staining assays of L929 cells and HUVEC cells. This application optimized the concentration of F127AcBr and loaded it into an MS hydrogel system. Excellent biocompatibility was confirmed in a diabetic mouse wound model using HE staining of mouse organs. Immunofluorescence staining against Staphylococcus aureus further confirmed the good antibacterial activity of F127AcBr.

The invention belongs to the field of medical supplies, and discloses a medical fever cooling patch and a preparation method thereof. The medical fever cooling patch is prepared from the following raw materials in percentage by mass: 0.1%-2% of carrageenan, 0.02%-2% of potassium chloride, 0.02%-2% of konjac glucomannan, 0.02%-2% of maltodextrin, 0.01%-2% of potassium citrate, 0.01%-2% of sodium chloride, 0.02%-2% of edible glucose, 0.01%-2% of xanthan gum, 0.1%-10% of a carboxymethyl chitosan-modified activated zeolite composite material, 0.00001%-0.01% of a coloring agent and the balance of water. The water content of the fever cooling patch can be larger than 90%, and the cooling degree, the continuous cooling time, the good viscosity and other performance are effectively guaranteed. The electronegativity of CMCS in the carboxymethyl chitosan-modified activated zeolite composite material and the electronegativity of the modified activated zeolite have a synergistic effect, so that no preservative is added, the cytotoxicity of the zeolite is greatly reduced, the biological evaluation of the medical fever cooling patch meets the requirements, and the survival rate of L929 cells is greater than 90%.

The invention belongs to the technical field of protein, and relates to a peptide for preventing collagen loss and a preparation method thereof. The amino acid sequence of the peptide is KSYELPDGQVITIG, and the key active fragment of the peptide is ELPDGQVIT. The peptide is obtained by performing enzymolysis on degreased maggot powder with alkaline protease, trypsin, papain, neutral protease and flavourzyme. The peptide can inhibit the expression of MMP1 and MMP9 in L929 cells after UVA irradiation, and alleviate the loss of collagen.

The present invention discloses a shell nacre-derived anti-inflammatory active peptide and its application in the preparation of skin repair products. The active peptide GEIRYEYF provided by the present invention has a concentration-dependent inhibition rate on NO release, and at a concentration of 200 μg / mL, NO release decreases by 54.32 ± 2.13%; it can also significantly reduce the secretion of pro-inflammatory cytokines TNF‑α and IL‑6 of RAW264.7 macrophages, and increase the secretion of anti-inflammatory cytokine IL‑10, and it is dose-dependent, with the highest concentration affecting IL‑6 secretion by 47.76 ± 1.02%, TNF‑α secretion by 42.01 ± 4.64%, and IL‑10 secretion by 41.71 ± 1.67%, with good anti-inflammatory activity. In addition, the active peptide has a significant proliferative effect on L929 cells, indicating that it has the potential to promote skin wound healing.

This invention belongs to the field of protein technology and relates to a peptide that prevents collagen loss and its preparation method. The amino acid sequence of the peptide is KSYELPDGQVITIG, with the key active fragment being ELPDGQVIT. The peptide is obtained by enzymatic hydrolysis of defatted grain insect powder using alkaline protease, trypsin, papain, neutral protease, and flavor protease. This peptide can inhibit the expression of MMP1 and MMP9 in L929 cells after UVA irradiation, thus alleviating collagen loss.

The invention discloses modified hyaluronic acid as well as a modification process and application thereof, and particularly relates to a method for chemically modifying hyaluronic acid by taking glutathione (GSH) as a functional molecule on the basis of a modification strategy of succinic anhydride bridged acylation on hyaluronic acid: under an alkaline condition, after ring opening of succinic anhydride, forming an ester bond with hydroxyl of hyaluronic acid, so as to obtain the modified hyaluronic acid. And at the same time, the other carboxyl group is condensed with the amino group of GSH to generate an amido bond, and the modified hyaluronic acid with a three-dimensional network structure is constructed. Performance tests show that the glutathione grafting rate of the obtained modified hyaluronic acid is up to 16.4%, the oxidation resistance is remarkably superior to that of unmodified hyaluronic acid, the enzymolysis resistance is reduced from 11.98% to 5.12%, the original moisturizing performance is not influenced, and the modified hyaluronic acid has no remarkable toxicity to L929 cells. According to the process provided by the invention, the oxidation resistance and enzyme stability of HA are effectively improved, and a new way is provided for application of HA in the field of anti-aging skin care.